FDA Accepts Application for CAVHANZA (Nilotinib) by FLEX PHARMA
The FDA has accepted the New Drug Application (NDA) for CAVHANZA, a nilotinib-based treatment.
Company
Pharmaceutical intelligence for FLEX PHARMA with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.